Zixing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zixing Wang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Jingmei Jiang
Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China
6 shared publications Wei Han
Beijing Municipal Geriatric Medical Research Center, Beijing Geriatric Healthcare Center, Beijing, China
6 shared publicationsYaoda Hu
Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China
6 shared publicationsRan Fei
Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
5 shared publicationsDongbo Chen
Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
3 shared publicationsShaoping She
Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Communications Medicine
Multi-agent AI for liver disease guideline development and maintenance: a proof-of-concept study
- 7 October 2026
- Published by Springer Nature in Communications Medicine
Open AccessMulti-agent AI for liver disease guideline development and maintenance: a proof-of-concept study
- Open Access
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1719899
A simple score of sarcopenic obesity predicts all-cause mortality in patients with cirrhosis
Purpose: To evaluate the predictors and prognostic impact of sarcopenic obesity (Sa-O) on all-cause mortality in patients with cirrhosis. Methods: This retrospective cohort study included cirrhosis patients. Sa-O was defined using computed tomography at L3 level as a skeletal muscle index 2 /m 2 or 100 cm 2 . The primary outcome was all-cause mortality. A nomograph was developed based on identified predictors, generating the age–body mass index (BMI)–alcohol–hypertension (ABAH) score. Results: Among 769 cirrhosis patients (60.1% male; 45.5% aged ≥60 years; median follow-up: 4.3 [1.7–7.0] years), 129 (16.8%) were diagnosed with Sa-O. Multivariable analysis identified age (OR [odds ratio] 1.813, 95% confidence interval [CI] 1.210–2.718, p = 0.0040), BMI ≥ 28 kg/m 2 (OR 0.076, 95% CI 0.018–0.317, p = 0.0011), alcoholic liver disease (OR 1.685, 95% CI 1.078–2.634, p = 0.0220), and hypertension (OR 1.801, 95% CI 1.184–2.739, p = 0.0059) as independent predictors of Sa-O. As for BMI (OR 0.076), the limitations of BMI in reflecting body composition led to the counterintuitive research findings. When stratified by ABAH score into low (p = 0.026). The prognostic value of the ABAH score was analyzed using a Cox proportional hazards model by subgroups analysis. It showed significant prognostic value for all-cause mortality, with medium-score patients exhibiting a 1.53-fold increased risk (95% CI 1.12–2.09, p = 0.007) and high-score patients a 1.72-fold increased risk (95% CI 1.22–2.42, p = 0.002) compared to the low-score reference group. Conclusion: Sa-O in patients with cirrhosis is associated with age, BMI, alcoholic liver disease, and hypertension. The newly developed ABAH score, a composite clinical risk marker, predicted the probability of Sa-O and was associated with all-cause mortality in patients with cirrhosis.
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1719899
Open AccessA simple score of sarcopenic obesity predicts all-cause mortality in patients with cirrhosis
Purpose: To evaluate the predictors and prognostic impact of sarcopenic obesity (Sa-O) on all-cause mortality in patients with cirrhosis. Methods: This retrospective cohort study included cirrhosis patients. Sa-O was defined using computed tomography at L3 level as a skeletal muscle index 2 /m 2 or 100 cm 2 . The primary outcome was all-cause mortality. A nomograph was developed based on identified predictors, generating the age–body mass index (BMI)–alcohol–hypertension (ABAH) score. Results: Among 769 cirrhosis patients (60.1% male; 45.5% aged ≥60 years; median follow-up: 4.3 [1.7–7.0] years), 129 (16.8%) were diagnosed with Sa-O. Multivariable analysis identified age (OR [odds ratio] 1.813, 95% confidence interval [CI] 1.210–2.718, p = 0.0040), BMI ≥ 28 kg/m 2 (OR 0.076, 95% CI 0.018–0.317, p = 0.0011), alcoholic liver disease (OR 1.685, 95% CI 1.078–2.634, p = 0.0220), and hypertension (OR 1.801, 95% CI 1.184–2.739, p = 0.0059) as independent predictors of Sa-O. As for BMI (OR 0.076), the limitations of BMI in reflecting body composition led to the counterintuitive research findings. When stratified by ABAH score into low (p = 0.026). The prognostic value of the ABAH score was analyzed using a Cox proportional hazards model by subgroups analysis. It showed significant prognostic value for all-cause mortality, with medium-score patients exhibiting a 1.53-fold increased risk (95% CI 1.12–2.09, p = 0.007) and high-score patients a 1.72-fold increased risk (95% CI 1.22–2.42, p = 0.002) compared to the low-score reference group. Conclusion: Sa-O in patients with cirrhosis is associated with age, BMI, alcoholic liver disease, and hypertension. The newly developed ABAH score, a composite clinical risk marker, predicted the probability of Sa-O and was associated with all-cause mortality in patients with cirrhosis.
- Open Access
- 10 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Transparent and dynamic network-based risk assessment for development of hepatic encephalopathy
Background Hepatic encephalopathy is a debilitating and resource-intensive complication of cirrhosis, with high prevalence, frequent hospitalizations, and poor prognosis. Precise and dynamic identification of at-risk individuals remains a major clinical challenge. Methods Combining expert knowledge with data-driven methodologies, we proposed a network-based risk assessment model by analyzing the inter-connections between cirrhotic complications and using routinely available blood test results. The model was developed (n = 2789) and validated (n = 698) in multi-etiology cirrhosis cohorts. Results Here we show hepatic encephalopathy as a pivotal nexus in the cirrhotic complication cascade. The presence of ascites (adjusted relative risk: 4.8), gastroesophageal varices (3.6), peritonitis (2.2), hepatorenal syndrome (2.1), gastroesophageal variceal hemorrhage (1.9) and hepatocellular carcinoma (1.5) is related with subsequent hepatic encephalopathy; all p < 0.05. Nine of 980 tests (ammonia, international normalized ratio, red cell distribution width standard deviation, fibrinogen, triglycerides, mean corpuscular hemoglobin, absolute neutrophil count, sodium, and total CO2) are selected through a stringent process encompassing clinical utility, expert agreement, risk direction clarity, and information non-redundancy. The network-based model accurately predicts hepatic encephalopathy risk in both cross-sectional and longitudinal settings, AUROC = 0.926 (95% confidence interval: 0.882-0.962) and 0.962 (0.933-0.984), respectively. It is compatible with missing data (i.e., using partially observed information) and offers flexible clinical implementation through a simple tool-free method and smart device integration. Clinical utility spans patient risk stratification, dynamic risk monitoring, optimized screening, and hepatic encephalopathy-related complication prevention. Conclusions This network-based approach provides transparent, precise and dynamic risk assessment in hepatic encephalopathy management, with potential to improve clinical outcomes in cirrhotic patients.
- 10 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessTransparent and dynamic network-based risk assessment for development of hepatic encephalopathy
Background Hepatic encephalopathy is a debilitating and resource-intensive complication of cirrhosis, with high prevalence, frequent hospitalizations, and poor prognosis. Precise and dynamic identification of at-risk individuals remains a major clinical challenge. Methods Combining expert knowledge with data-driven methodologies, we proposed a network-based risk assessment model by analyzing the inter-connections between cirrhotic complications and using routinely available blood test results. The model was developed (n = 2789) and validated (n = 698) in multi-etiology cirrhosis cohorts. Results Here we show hepatic encephalopathy as a pivotal nexus in the cirrhotic complication cascade. The presence of ascites (adjusted relative risk: 4.8), gastroesophageal varices (3.6), peritonitis (2.2), hepatorenal syndrome (2.1), gastroesophageal variceal hemorrhage (1.9) and hepatocellular carcinoma (1.5) is related with subsequent hepatic encephalopathy; all p < 0.05. Nine of 980 tests (ammonia, international normalized ratio, red cell distribution width standard deviation, fibrinogen, triglycerides, mean corpuscular hemoglobin, absolute neutrophil count, sodium, and total CO2) are selected through a stringent process encompassing clinical utility, expert agreement, risk direction clarity, and information non-redundancy. The network-based model accurately predicts hepatic encephalopathy risk in both cross-sectional and longitudinal settings, AUROC = 0.926 (95% confidence interval: 0.882-0.962) and 0.962 (0.933-0.984), respectively. It is compatible with missing data (i.e., using partially observed information) and offers flexible clinical implementation through a simple tool-free method and smart device integration. Clinical utility spans patient risk stratification, dynamic risk monitoring, optimized screening, and hepatic encephalopathy-related complication prevention. Conclusions This network-based approach provides transparent, precise and dynamic risk assessment in hepatic encephalopathy management, with potential to improve clinical outcomes in cirrhotic patients.
- Open Access
- 30 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Age, frequency, and strategy optimization for organized colorectal cancer screening: a decision analysis conducted in China for the years 2023–2038
The colorectal cancer mortality rate in China has exceeded that in many developing countries and is expected to further increase owing to multiple factors, including the aging population. However, the optimal policy for colorectal cancer screening is unknown. We synthesized the most up-to-date data using a 12-state Markov model populated with a cohort of Chinese men and women born during 1949–1988, and evaluated 16 conventional and 40 risk-tailored schemes for colorectal cancer screening, considering possible combinations of age (starting at 40 + years and ending at 75 years), frequency, and strategy (standard colonoscopy, fecal immunochemical testing with colonoscopy if positive, or risk-tailored). We projected the incidence and mortality of CRC, cost, and quality-adjusted life years for 2023–2038; and performed incremental cost-effectiveness, probability acceptability, and sensitivity analyses to identify the optimal scheme and the factors affecting this choice. By 2038, all standard colonoscopy, colonoscopy following fecal immunochemical testing, and risk-tailored schemes were effective in reshaping China’s colorectal cancer trajectory, with relative reductions in colorectal cancer incidence and mortality rates of up to 34% and 33.7%, respectively, versus no screening. Two standard colonoscopy, one colonoscopy following fecal immunochemical testing, and four risk-tailored schemes were efficient using a starting age of 40 years. Among these options, a risk-tailored scheme (standard colonoscopy every 5 years for high-risk and annual fecal immunochemical testing screening for moderate-to-low-risk) had a high probability (31.1%) of being optimal (with ≥ 40% uptake for a high-risk population, in particular), given China’s present per capita gross domestic product, and would yield the highest gain in quality-adjusted life years in 17 of 31 provinces. Our findings suggest the commencement of colorectal cancer screening at 40 years of age in China, and that risk-tailored and some conventional schemes would be effective and cost-efficient. These findings should be valuable for policy-making regarding cancer control and resource allocation.
- 30 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Open AccessAge, frequency, and strategy optimization for organized colorectal cancer screening: a decision analysis conducted in China for the years 2023–2038
The colorectal cancer mortality rate in China has exceeded that in many developing countries and is expected to further increase owing to multiple factors, including the aging population. However, the optimal policy for colorectal cancer screening is unknown. We synthesized the most up-to-date data using a 12-state Markov model populated with a cohort of Chinese men and women born during 1949–1988, and evaluated 16 conventional and 40 risk-tailored schemes for colorectal cancer screening, considering possible combinations of age (starting at 40 + years and ending at 75 years), frequency, and strategy (standard colonoscopy, fecal immunochemical testing with colonoscopy if positive, or risk-tailored). We projected the incidence and mortality of CRC, cost, and quality-adjusted life years for 2023–2038; and performed incremental cost-effectiveness, probability acceptability, and sensitivity analyses to identify the optimal scheme and the factors affecting this choice. By 2038, all standard colonoscopy, colonoscopy following fecal immunochemical testing, and risk-tailored schemes were effective in reshaping China’s colorectal cancer trajectory, with relative reductions in colorectal cancer incidence and mortality rates of up to 34% and 33.7%, respectively, versus no screening. Two standard colonoscopy, one colonoscopy following fecal immunochemical testing, and four risk-tailored schemes were efficient using a starting age of 40 years. Among these options, a risk-tailored scheme (standard colonoscopy every 5 years for high-risk and annual fecal immunochemical testing screening for moderate-to-low-risk) had a high probability (31.1%) of being optimal (with ≥ 40% uptake for a high-risk population, in particular), given China’s present per capita gross domestic product, and would yield the highest gain in quality-adjusted life years in 17 of 31 provinces. Our findings suggest the commencement of colorectal cancer screening at 40 years of age in China, and that risk-tailored and some conventional schemes would be effective and cost-efficient. These findings should be valuable for policy-making regarding cancer control and resource allocation.
- 28 September 2024
- Published by Wiley in Helicobacter
- Vol. 29 (5) , e13139
Tracking the Helicobacter pylori Epidemic in Adults and Children in China
Background: The Helicobacter pylori epidemic in China accounts for up to a third of gastric cancers worldwide. We aim to monitor the temporal and spatial dynamics of H. pylori infection in both adults and children across China.Materials and Methods: We developed a surveillance system consisting of a data collection component that harnessed survey reports in natural populations and an analysis component that accounted for the differences in survey time and location, population age structure, and H. pylori detection method. System outputs were estimates of the prevalence of H. pylori in adults and children (aged ≤ 14 years) presented at three hierarchical levels (regional, provincial, and prefectural).Results: The overall prevalence of H. pylori infection declined sharply in adults (63.3%, 52.5%, 43.4%, and 38.7%) and less sharply in children (23.1%, 26.1%, 16.0%, and 15.7%) in 1983–1999, 2000–2009, 2010–2014, and 2015–2019, respectively. The changes were asynchronous across regions, with the most marked declines in the Northwest, the Hong Kong‐Macao‐Taiwan region, and the East. We estimated that 457.6 million adults and 44.5 million children have been infected with H. pylori, with cross‐province disparities in prevalence ranging from 24.3% to 69.3% among adults and 2.9% to 46.3% among children. In general, the risk level of gastric cancer increased as the prevalence of H. pylori increased. The correlation was statistically significant for both adult men (Spearman coefficient of correlation: 0.393, p = 0.0146) and women (0.470, p = 0.0029).Conclusions: The tracking system would be important for the continuous and stratified tracking of the Helicobacter pylori epidemic across China and can be used to furnish an evidence base for the formulation of tailored prevention strategies.
- 28 September 2024
- Published by Wiley in Helicobacter
- Vol. 29 (5) , e13139
Tracking the Helicobacter pylori Epidemic in Adults and Children in China
Background: The Helicobacter pylori epidemic in China accounts for up to a third of gastric cancers worldwide. We aim to monitor the temporal and spatial dynamics of H. pylori infection in both adults and children across China.Materials and Methods: We developed a surveillance system consisting of a data collection component that harnessed survey reports in natural populations and an analysis component that accounted for the differences in survey time and location, population age structure, and H. pylori detection method. System outputs were estimates of the prevalence of H. pylori in adults and children (aged ≤ 14 years) presented at three hierarchical levels (regional, provincial, and prefectural).Results: The overall prevalence of H. pylori infection declined sharply in adults (63.3%, 52.5%, 43.4%, and 38.7%) and less sharply in children (23.1%, 26.1%, 16.0%, and 15.7%) in 1983–1999, 2000–2009, 2010–2014, and 2015–2019, respectively. The changes were asynchronous across regions, with the most marked declines in the Northwest, the Hong Kong‐Macao‐Taiwan region, and the East. We estimated that 457.6 million adults and 44.5 million children have been infected with H. pylori, with cross‐province disparities in prevalence ranging from 24.3% to 69.3% among adults and 2.9% to 46.3% among children. In general, the risk level of gastric cancer increased as the prevalence of H. pylori increased. The correlation was statistically significant for both adult men (Spearman coefficient of correlation: 0.393, p = 0.0146) and women (0.470, p = 0.0029).Conclusions: The tracking system would be important for the continuous and stratified tracking of the Helicobacter pylori epidemic across China and can be used to furnish an evidence base for the formulation of tailored prevention strategies.
- Open Access
- 1 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (13) , e7436
Reinforcement learning for individualized lung cancer screening schedules: A nested case–control study
Background: The current guidelines for managing screen‐detected pulmonary nodules offer rule‐based recommendations for immediate diagnostic work‐up or follow‐up at intervals of 3, 6, or 12 months. Customized visit plans are lacking.Purpose: To develop individualized screening schedules using reinforcement learning (RL) and evaluate the effectiveness of RL‐based policy models.Methods: Using a nested case–control design, we retrospectively identified 308 patients with cancer who had positive screening results in at least two screening rounds in the National Lung Screening Trial. We established a control group that included cancer‐free patients with nodules, matched (1:1) according to the year of cancer diagnosis. By generating 10,164 sequence decision episodes, we trained RL‐based policy models, incorporating nodule diameter alone, combined with nodule appearance (attenuation and margin) and/or patient information (age, sex, smoking status, pack‐years, and family history). We calculated rates of misdiagnosis, missed diagnosis, and delayed diagnosis, and compared the performance of RL‐based policy models with rule‐based follow‐up protocols (National Comprehensive Cancer Network guideline; China Guideline for the Screening and Early Detection of Lung Cancer).Results: We identified significant interactions between certain variables (e.g., nodule shape and patient smoking pack‐years, beyond those considered in guideline protocols) and the selection of follow‐up testing intervals, thereby impacting the quality of the decision sequence. In validation, one RL‐based policy model achieved rates of 12.3% for misdiagnosis, 9.7% for missed diagnosis, and 11.7% for delayed diagnosis. Compared with the two rule‐based protocols, the three best‐performing RL‐based policy models consistently demonstrated optimal performance for specific patient subgroups based on disease characteristics (benign or malignant), nodule phenotypes (size, shape, and attenuation), and individual attributes.Conclusions: This study highlights the potential of using an RL‐based approach that is both clinically interpretable and performance‐robust to develop personalized lung cancer screening schedules. Our findings present opportunities for enhancing the current cancer screening system.
- 1 July 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (13) , e7436
Open AccessReinforcement learning for individualized lung cancer screening schedules: A nested case–control study
Background: The current guidelines for managing screen‐detected pulmonary nodules offer rule‐based recommendations for immediate diagnostic work‐up or follow‐up at intervals of 3, 6, or 12 months. Customized visit plans are lacking.Purpose: To develop individualized screening schedules using reinforcement learning (RL) and evaluate the effectiveness of RL‐based policy models.Methods: Using a nested case–control design, we retrospectively identified 308 patients with cancer who had positive screening results in at least two screening rounds in the National Lung Screening Trial. We established a control group that included cancer‐free patients with nodules, matched (1:1) according to the year of cancer diagnosis. By generating 10,164 sequence decision episodes, we trained RL‐based policy models, incorporating nodule diameter alone, combined with nodule appearance (attenuation and margin) and/or patient information (age, sex, smoking status, pack‐years, and family history). We calculated rates of misdiagnosis, missed diagnosis, and delayed diagnosis, and compared the performance of RL‐based policy models with rule‐based follow‐up protocols (National Comprehensive Cancer Network guideline; China Guideline for the Screening and Early Detection of Lung Cancer).Results: We identified significant interactions between certain variables (e.g., nodule shape and patient smoking pack‐years, beyond those considered in guideline protocols) and the selection of follow‐up testing intervals, thereby impacting the quality of the decision sequence. In validation, one RL‐based policy model achieved rates of 12.3% for misdiagnosis, 9.7% for missed diagnosis, and 11.7% for delayed diagnosis. Compared with the two rule‐based protocols, the three best‐performing RL‐based policy models consistently demonstrated optimal performance for specific patient subgroups based on disease characteristics (benign or malignant), nodule phenotypes (size, shape, and attenuation), and individual attributes.Conclusions: This study highlights the potential of using an RL‐based approach that is both clinically interpretable and performance‐robust to develop personalized lung cancer screening schedules. Our findings present opportunities for enhancing the current cancer screening system.
- Open Access
- 8 July 2023
- Published by Springer Nature in npj Clean Water
- Vol. 6 (1) , 1-9
Spatial association of surface water quality and human cancer in China
Little is known about the association between surface water quality and cancer incidence, especially in China. Drinking water quality has been linked to the incidence of several cancers in individual-level studies. However, few studies have attempted to examine multiple pollutants and multiple cancers at population level. This study used water monitoring and population-level cancer data from across China to examine spatial associations between water pollutants and types of cancer. We found a “dose–response” relationship between the number of pollutants present at high levels and cancer incidence. These results provide evidence of a nationwide spatial association between water quality and cancer in China. The precise relationship varies with cancers and pollutants. However, the overall consistency of the “dose–response” relationship suggests that surface water quality is an important factor in cancer incidence. Our findings highlight new issues such as the changing effects when different pollutants co-exist and an increasing number of new cancer cases partially attributable to poor water quality. Our work also points to some ways to deal with these challenges.
- 8 July 2023
- Published by Springer Nature in npj Clean Water
- Vol. 6 (1) , 1-9
Open AccessSpatial association of surface water quality and human cancer in China
Little is known about the association between surface water quality and cancer incidence, especially in China. Drinking water quality has been linked to the incidence of several cancers in individual-level studies. However, few studies have attempted to examine multiple pollutants and multiple cancers at population level. This study used water monitoring and population-level cancer data from across China to examine spatial associations between water pollutants and types of cancer. We found a “dose–response” relationship between the number of pollutants present at high levels and cancer incidence. These results provide evidence of a nationwide spatial association between water quality and cancer in China. The precise relationship varies with cancers and pollutants. However, the overall consistency of the “dose–response” relationship suggests that surface water quality is an important factor in cancer incidence. Our findings highlight new issues such as the changing effects when different pollutants co-exist and an increasing number of new cancer cases partially attributable to poor water quality. Our work also points to some ways to deal with these challenges.
- 16 January 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 92 (4) , 295-302
Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta‐analysis based on individual patient data
Background and Objective: Parathyroid carcinoma (PC) is a rare malignant neoplasm with a relatively poor prognosis. The loss of parafibromin expression or the presence of CDC73 mutation has been found to be remarkably associated with malignancy in parathyroid tumours. However, the prognostic role of them in PC has not yet been shown due to sampling limitations. We conducted a systematic review and meta‐analysis based on individual patient data to clarify the performance of parafibromin immunohistochemical staining and CDC73 gene sequencing in predicting outcomes for patients PC.Methods: Published studies from PubMed/MEDLINE, EMBASE, Cochrane and Scopus Databases were searched using the terms ‘parafibromin’, ‘CDC73’, ‘HRPT2’ and ‘parathyroid’ to identify eligible studies. From the included studies, the survival data of patients with PC were extracted, and a Cox proportional hazards model was used to assess hazard ratio (HR) for disease‐free survival (DFS) and overall survival (OS).Results: A total of 193 patients from 9 studies were included in this survival analysis. Negative immunohistochemical staining of parafibromin was shown to be a risk factor for recurrence/metastasis (HR 2.73, P = .002) and death (HR 2.54, P = .004). Patient age ≥ 50 years was significantly related to lower OS (HR 2.37, P = .004) but not to DFS. CDC73 mutation was not statistically related to DFS or OS.Conclusions: Negative parafibromin staining indicated a higher risk of recurrence/metastasis and mortality. The immunohistochemical staining of parafibromin seems to be more promising in predicting outcomes for patients with PC than the sequencing of CDC73.
- 16 January 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 92 (4) , 295-302
Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta‐analysis based on individual patient data
Background and Objective: Parathyroid carcinoma (PC) is a rare malignant neoplasm with a relatively poor prognosis. The loss of parafibromin expression or the presence of CDC73 mutation has been found to be remarkably associated with malignancy in parathyroid tumours. However, the prognostic role of them in PC has not yet been shown due to sampling limitations. We conducted a systematic review and meta‐analysis based on individual patient data to clarify the performance of parafibromin immunohistochemical staining and CDC73 gene sequencing in predicting outcomes for patients PC.Methods: Published studies from PubMed/MEDLINE, EMBASE, Cochrane and Scopus Databases were searched using the terms ‘parafibromin’, ‘CDC73’, ‘HRPT2’ and ‘parathyroid’ to identify eligible studies. From the included studies, the survival data of patients with PC were extracted, and a Cox proportional hazards model was used to assess hazard ratio (HR) for disease‐free survival (DFS) and overall survival (OS).Results: A total of 193 patients from 9 studies were included in this survival analysis. Negative immunohistochemical staining of parafibromin was shown to be a risk factor for recurrence/metastasis (HR 2.73, P = .002) and death (HR 2.54, P = .004). Patient age ≥ 50 years was significantly related to lower OS (HR 2.37, P = .004) but not to DFS. CDC73 mutation was not statistically related to DFS or OS.Conclusions: Negative parafibromin staining indicated a higher risk of recurrence/metastasis and mortality. The immunohistochemical staining of parafibromin seems to be more promising in predicting outcomes for patients with PC than the sequencing of CDC73.
- Open Access
- 24 June 2019
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 21 (6) , e13576
Key Issues in the Development of an Evidence-Based Stratified Surgical Patient Safety Improvement Information System: Experience From a Multicenter Surgical Safety Program
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Several large surgical complication reporting systems and system-based interventions have been developed and have made remarkable progress in the past two decades. However, these have either mainly focused on reporting complications, and played a limited role in guiding practice, or have provided non-selective interventions to all patients, perhaps imposing unnecessary burdens on frontline medical staff. We have therefore developed an evidence-based stratified surgical safety information system based on a multi-center surgical safety improvement program. This article discusses some critical issues in the process of developing this information system, including (1) decisions about data gathering; (2) establishing and sharing knowledge; (3) developing functions for the system; (4) system implementation; and (5) evaluation and continuous improvement. Using examples drawn from above mentioned surgical safety improvement program, we have shown how this type of system can be fitted into day-to-day clinical practice and how it can guide medical practice by incorporating inherent patient-related risk, and providing tailored interventions for patients with different levels of risk. We concluded that multidisciplinary collaboration, including experts in the fields of healthcare (including senior staff in surgery, nursing and anesthesia), data science, healthcare management and health IT, can help to build an evidence-based stratified surgical patient safety improvement system. This can provide an information-intensified surgical safety learning platform and therefore benefit surgical patients by delivering tailored interventions, and an integrated workflow.
- 24 June 2019
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 21 (6) , e13576
Open AccessKey Issues in the Development of an Evidence-Based Stratified Surgical Patient Safety Improvement Information System: Experience From a Multicenter Surgical Safety Program
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Several large surgical complication reporting systems and system-based interventions have been developed and have made remarkable progress in the past two decades. However, these have either mainly focused on reporting complications, and played a limited role in guiding practice, or have provided non-selective interventions to all patients, perhaps imposing unnecessary burdens on frontline medical staff. We have therefore developed an evidence-based stratified surgical safety information system based on a multi-center surgical safety improvement program. This article discusses some critical issues in the process of developing this information system, including (1) decisions about data gathering; (2) establishing and sharing knowledge; (3) developing functions for the system; (4) system implementation; and (5) evaluation and continuous improvement. Using examples drawn from above mentioned surgical safety improvement program, we have shown how this type of system can be fitted into day-to-day clinical practice and how it can guide medical practice by incorporating inherent patient-related risk, and providing tailored interventions for patients with different levels of risk. We concluded that multidisciplinary collaboration, including experts in the fields of healthcare (including senior staff in surgery, nursing and anesthesia), data science, healthcare management and health IT, can help to build an evidence-based stratified surgical patient safety improvement system. This can provide an information-intensified surgical safety learning platform and therefore benefit surgical patients by delivering tailored interventions, and an integrated workflow.
- Open Access
- 11 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 348
Is exposure to tobacco associated with extrahepatic cholangiocarcinoma epidemics? A retrospective proportional mortality study in China
Extrahepatic cholangiocarcinoma (ECC) has become one of the most rapidly increasing malignancies in China during recent decades. The relationship between tobacco exposure and ECC epidemics is unclear; this study aimed to explore this relationship. We included 55,806 participants aged 30 years or older from the National Mortality and Smoking Survey of China. Smoking in participants and spouses was defined as 1 cigarette or more per day for up to 1 year. Spouses’ smoking was taken as a measure of exposure to passive smoking. Smoking information in 1980 was ascertained and outcomes were defined as ECC mortality during 1986–1988. We found that either passive or active smoking increased the risk of death from ECC by 20% (risk ratio [RR], 1.20; 95% confidence interval [CI], 0.99–1.47), compared with no exposure to any tobacco. This risk was a notable 98% (RR, 1.98; 95% CI, 1.49–2.64) for individuals exposed to passive plus active smoking. These findings were highly consistent among men and women. Pathology-based analyses showed dose-response relationships of ECC with pack-years for all types of smoking exposure (Ps for trend < 0.05); the RR reached 2.75 (95% CI, 1.20–6.30) in individuals exposed to combined smoking with the highest exposure dose. The findings were similar for non-pathology-based analysis. This study indicates that tobacco exposure increases ECC risk. Given the dramatic increase of exposure to secondhand smoke and patients with ECC, an inadequate provision of smoke-free environments could be contributing to ECC epidemics and could further challenge public health and medical services, based on the current disease spectrum.
- 11 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 348
Open AccessIs exposure to tobacco associated with extrahepatic cholangiocarcinoma epidemics? A retrospective proportional mortality study in China
Extrahepatic cholangiocarcinoma (ECC) has become one of the most rapidly increasing malignancies in China during recent decades. The relationship between tobacco exposure and ECC epidemics is unclear; this study aimed to explore this relationship. We included 55,806 participants aged 30 years or older from the National Mortality and Smoking Survey of China. Smoking in participants and spouses was defined as 1 cigarette or more per day for up to 1 year. Spouses’ smoking was taken as a measure of exposure to passive smoking. Smoking information in 1980 was ascertained and outcomes were defined as ECC mortality during 1986–1988. We found that either passive or active smoking increased the risk of death from ECC by 20% (risk ratio [RR], 1.20; 95% confidence interval [CI], 0.99–1.47), compared with no exposure to any tobacco. This risk was a notable 98% (RR, 1.98; 95% CI, 1.49–2.64) for individuals exposed to passive plus active smoking. These findings were highly consistent among men and women. Pathology-based analyses showed dose-response relationships of ECC with pack-years for all types of smoking exposure (Ps for trend < 0.05); the RR reached 2.75 (95% CI, 1.20–6.30) in individuals exposed to combined smoking with the highest exposure dose. The findings were similar for non-pathology-based analysis. This study indicates that tobacco exposure increases ECC risk. Given the dramatic increase of exposure to secondhand smoke and patients with ECC, an inadequate provision of smoke-free environments could be contributing to ECC epidemics and could further challenge public health and medical services, based on the current disease spectrum.